CERS2 and hepatocellular carcinoma: Studies have reported that low LASS2 expression is associated with a poor prognosis for patients with hepatocellular carcinoma (HCC) [22] and suggested that the combination of LASS2 and TGF-β1 [22] or ASGR1 [23] may assist in predicting the prognosis.